IL246299A0 - History of Sorbibin and preparations containing them - Google Patents

History of Sorbibin and preparations containing them

Info

Publication number
IL246299A0
IL246299A0 IL246299A IL24629916A IL246299A0 IL 246299 A0 IL246299 A0 IL 246299A0 IL 246299 A IL246299 A IL 246299A IL 24629916 A IL24629916 A IL 24629916A IL 246299 A0 IL246299 A0 IL 246299A0
Authority
IL
Israel
Prior art keywords
survivin
derivatives
compositions containing
compositions
survivin derivatives
Prior art date
Application number
IL246299A
Other languages
English (en)
Hebrew (he)
Inventor
Markus Weigandt
Simon Geissler
Patrizia Boniforte
Joerg Plaschke
Stefan Jaekel
Roland Kellner
Thomas Rysiok
Pompalla Dirk Mueller
Kenneth Hance
Original Assignee
Markus Weigandt
Merck Patent Gmbh
Simon Geissler
Patrizia Boniforte
Joerg Plaschke
Stefan Jaekel
Roland Kellner
Thomas Rysiok
Pompalla Dirk Mueller
Kenneth Hance
Merck Patent Ges Mit Beschrankter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Markus Weigandt, Merck Patent Gmbh, Simon Geissler, Patrizia Boniforte, Joerg Plaschke, Stefan Jaekel, Roland Kellner, Thomas Rysiok, Pompalla Dirk Mueller, Kenneth Hance, Merck Patent Ges Mit Beschrankter Haftung filed Critical Markus Weigandt
Publication of IL246299A0 publication Critical patent/IL246299A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL246299A 2013-12-16 2016-06-16 History of Sorbibin and preparations containing them IL246299A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13005831 2013-12-16
PCT/EP2014/003384 WO2015090572A1 (en) 2013-12-16 2014-12-16 Survivin-directed cancer vaccine therapy

Publications (1)

Publication Number Publication Date
IL246299A0 true IL246299A0 (en) 2016-07-31

Family

ID=49884863

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246299A IL246299A0 (en) 2013-12-16 2016-06-16 History of Sorbibin and preparations containing them

Country Status (8)

Country Link
US (1) US20160279213A1 (cg-RX-API-DMAC7.html)
EP (1) EP3083663A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017501172A (cg-RX-API-DMAC7.html)
CN (1) CN105873941A (cg-RX-API-DMAC7.html)
AU (1) AU2014365888B2 (cg-RX-API-DMAC7.html)
CA (1) CA2933705A1 (cg-RX-API-DMAC7.html)
IL (1) IL246299A0 (cg-RX-API-DMAC7.html)
WO (1) WO2015090572A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
CN109125741B (zh) * 2018-08-13 2022-02-11 四川大学 透明质酸/dotap/生存素编码基因自组装的三元复合物制剂及其制备方法
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
CA3119910A1 (en) * 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
CN111983240B (zh) * 2020-08-27 2023-11-21 天津大学 一种产气荚膜梭菌α毒素可视化检测的方法
JP7318983B2 (ja) * 2021-12-21 2023-08-01 株式会社アビー 細胞凍結保存液、及び細胞凍結方法
CN116617414B (zh) * 2023-03-31 2024-04-05 中国农业大学 一种脂质体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
CN1316037C (zh) * 2003-12-19 2007-05-16 叶尚勉 检测待测标本中生存素表达量的诊断试剂、检测方法及应用
DK1853305T3 (en) * 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
AU2009236306B2 (en) * 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids

Also Published As

Publication number Publication date
AU2014365888B2 (en) 2018-12-06
EP3083663A1 (en) 2016-10-26
US20160279213A1 (en) 2016-09-29
WO2015090572A1 (en) 2015-06-25
JP2017501172A (ja) 2017-01-12
CA2933705A1 (en) 2015-06-25
CN105873941A (zh) 2016-08-17
AU2014365888A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
IL240290A0 (en) History of pyridazinone-amide and pharmaceutical preparations containing them
GB201304662D0 (en) Compositions
ZA201505790B (en) Amatoxin derivatives
GB201319525D0 (en) Composition
EP2968108A4 (en) COSMETIC COMPOSITIONS
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
GB201313615D0 (en) Compositions
PT3091991T (pt) Composições imunomodulatórias
GB201319540D0 (en) Composition
GB201318489D0 (en) Composition
EP3006525A4 (en) ASPHALT-URETHANE COMPOSITION
GB201317105D0 (en) Novel Composition
GB201320919D0 (en) Composition
GB201320303D0 (en) Composition
GB201317388D0 (en) Composition
GB201319538D0 (en) Composition
GB201306984D0 (en) Composition
GB201320432D0 (en) Novel formulation
GB201317196D0 (en) Composition
GB201307622D0 (en) Composition
ZA201505650B (en) New compositions
GB201320962D0 (en) Compositions
GB201316463D0 (en) Novel compositions
GB201319923D0 (en) Novel composition
GB201317718D0 (en) Novel formulation